Journey Towards Accurate and Fast Non-Invasive Mapping of Heart Bio Signals

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.


Rakesh Sethi, Vice President, General Manager
Advanced Product Development
TDK U.S.A. Corporation

Yasushi Terazono, Sr. Scientist
TDK U.S.A. Corporation

Tomohiko Shibuya, Manager of
PicoTesla Sensor Solutions
TDK Corporation

Three years ago, in Japan, the TDK room temperature, magnetocardiography (MCG) real-time imaging platform was deployed for investigational use only in a multi-year trial. The key goal has been to provide non-invasive mapping of bio signals in the heart. One main objective is to develop a sensing platform that can resolve the spatial and temporal properties of ventricular arrhythmias in real time. MCG has the potential to non-invasively locate the successful ablation site in advance, which could potentially shorten the duration of procedures, improve accuracy and reduce the overall radiation dose. Combined with novel, emerging non-invasive external radiation ablation therapy, TDK’s MCG platform could disrupt traditional methods by powering a new generation of entirely non-invasive heart arrhythmia therapy.

With a wide portfolio of signal processing algorithms, TDK is preparing a continuous roadmap of improved sensor sensitivity to extend non-invasive 3D mapping to the atria for atrial fibrillation mapping and ablation. TDK envisions forming and expanding its ecosystem of biomagnetic sensing with strategic partners working at the leading edge of sensor technology, by providing them with a set of tools for conducting independent research. This strategy should allow leading OEMs and startups to advance their technology roadmaps. In this article, we describe some key pain points for interventional cardiologists and electrophysiologists (EPs) working with currently available technologies.

Today the interventional cardiologist confronts multiple tradeoffs such as patient, nurse, and doctor safety; duration of procedure; ablation target location accuracy; value of arrhythmia origin and isthmus identification; and value of other substrates. The effectiveness of preoperative examinations for the identification of ablation sites remains a key concern. The current trend is towards invasive radio-ablation. Shortening of the procedure currently is of prime importance. Current procedures can last up to four hours (1). The MCG mapping method potentially may lead to a significant reduction in procedures’ times, to less than one hour.

Spatial resolution targets currently acceptable are in the range of 2-10 mm. MCG could potentially enable such a possibility. Localizing an ablation site can be broken down into estimating its origin or isthmuses or paths of reentry, as well as the presence of other substrates. MCG mapping algorithms are now being developed to ascertain each of these electric foci and circuits.

The future non-invasive sensing ecosystem demands a critical look at all of the above tradeoffs. The TDK MCG 3D mapping system platform is being developed to become an ideal tool for meeting the critical needs of the OEMs, system architects, interventional cardiology doctors and Software-as-a-Service (SaaS) companies involved in manufacturing and measuring heart bio signals. MCG systems potentially allow OEMs to design tools that can provide faster turnaround times, better imaging, higher resolutions, lower costs and ultimately, positive outcomes.

Learn more about MCG with TDK, by contacting Additional details can be found in our product center and on our product page.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.